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INTRODUCTION
Approximately 75% of patients with testicular seminoma
present with Stage I disease. There are several management
options for this stage of seminoma, including adjuvant
radiotherapy (RT), surveillance or chemotherapy.The traditional
management approach for Stage I pure seminoma has been
radical inguinal orchidectomy followed by adjuvant external
beam RT to the para-aortic and ipsilateral pelvic regions. With
follow up consisting of clinical examination, serum tumour
markers and chest X-ray (CXR), the long-term results are
excellent with relapse-free rates of 94–98%. With the use of
salvage chemotherapy, long-term survival approaches 100%.1–3
While the acute toxicity of RT is low, there has been increasing
concern with regards to potential long-term radiation-induced
morbidity, including impaired spermatogenesis, chronic
gastrointestinal complications and second malignancy. These
concerns, together with the availability of improved imaging
techniques and more effective salvage treatment for relapse,
have led to the exploration of alternative management
approaches and reduction of the intensity of RT. However, it is
important to ensure that these changes do not compromise the
current excellent survival outcomes.
A recent pooled analysis of four surveillance series
comprising 638 patients, with a median follow up of 7 years, has
reported a relapse rate of 18%.4 The majority of recurrences
(85–90%) are limited to the para-aortic lymph nodes, and are
successfully salvaged by RT. Although most first recurrences
occur within 2 years of orchidectomy, recurrences have been
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reported as late as 9 years from diagnosis.5–7 Thus, surveil-
lance, which requires intensive follow up over a long period,
depends upon both a motivated clinician and a compliant
patient. Given these caveats, surveillance is a viable thera-
peutic alternative as it appears to provide a survival rate
equivalent to that achieved with standard adjuvant RT.
Refinements to reduce the morbidity of RT have included
reduction of the target volume. The Medical Research Council
(MRC) trial comparing para-aortic and ipsilateral pelvic radia-
tion or ‘dog-leg’ (DL) to a para-aortic strip alone (PA) in 
478 patients reported no difference in disease-free or overall
survival between the two arms.8 The acute toxicity, specifically
haematologic, gonadal and gastrointestinal, was reduced in 
the PA arm. There were nine relapses in each arm, with four 
of those in the PA arm located in the pelvis. This was an
equivalence trial, powered to detect a difference in pelvic
relapse of greater than 3%, and thus, small differences in
outcomes might not have been detected.
There are reports of research utilizing one or two courses of
single-agent chemotherapy instead of adjuvant RT. A German
series of 93 patients treated with one cycle of carboplatin
resulted in a relapse-free survival of 91%, inferior to that
achieved with adjuvant RT (94–98%).9 By contrast, in a more
recent publication from Vienna using two cycles of carboplatin
in 107 men, there have been no relapses to date.10 Chemo-
therapy was generally well tolerated with minimal disruption to
normal lifestyle. However, larger numbers and longer follow up
are required to determine the late effects of this treatment.
With several treatment alternatives available for the manage-
ment of Stage I seminoma of the testis, as well as variation with
respect to radiotherapy treatment fields and prescribed 
doses, a survey was conducted among radiation oncologists 
to evaluate preferred management approaches to Stage I
testicular seminoma.
METHODS AND MATERIALS
A survey was conducted between March and April 2001.
The survey was sent to 174 practicing radiation oncologists
registered with the Royal Australian and New Zealand College
of Radiologists (RANZCR).
The Questionnaire consisted of three sections: (i) manage-
ment approaches including the extent of baseline radiological
investigations, whether or not the radiation oncologist dis-
cussed a surveillance option with their patients and, if so, the
clinician’s estimate of the proportion of patients opting for this
strategy; (ii) a ranking of management options in the absence or
presence of patient concern about fertility; and (iii) radiation
oncologists were asked to nominate their preferred treatment
volume and dose-fractionation schedule.
For proponents of the PA volume, a question concerning the
impact of the MRC trial upon modifying their treatment volume
was asked. Finally, again for oncologists treating the PA alone, 
a question regarding the frequency of CT scans for follow up of
the pelvis, every 6 months, annually or not at all.
A similar survey was distributed in Canada and the USA
between January and March 2001.11 Sections 1 and 3 were
identical in both the North American and Australasian surveys,
allowing comparison between the regions with respect to these
parts of the survey. In North America, distribution of the survey
differed to the Australasian survey. In Canada, the survey was sent
to 93 radiation oncologists treating genitourinary tumours. In the
USA, the survey was limited to the 36 Genitourinary Committee
members of the Radiation Therapy Oncology Group (RTOG).
RESULTS
Seventy-four questionnaires were returned by the end of April.
All responders were practicing radiation oncologists based in
Australia, New Zealand and Singapore.
Radiological investigations
One person did not respond to any parts of the question
regarding baseline investigations. Of 73 radiation oncologists
who replied, all routinely performed a CT scan of the abdomen
and pelvis. When evaluating the thorax, 21 ordered a CXR
(29%) and 28 ordered a chest CT scan alone (38%), while 24
obtained both (33%). Only one radiation oncologist requested 
a lymphangiogram (1.4%). Three stated that they routinely
performed ultrasound of the contralateral testis.
Management options
Just over half (54%) of the respondents stated that they offered
their patients the option of surveillance. Among those offering
surveillance, they estimated that 5% or less (range 0–30%) of
the patients in their practice would choose this option (Table 1).
Radiation oncologists were asked to rank, in order of pref-
erence, three management options in the presence or absence 
of concern about fertility. The three management options were:
(i) surveillance with reservation of RT or chemotherapy for
relapse; (ii) postoperative adjuvant RT using either PA or DL field;
and (iii) postoperative adjuvant single-agent chemotherapy.
In patients for whom fertility was a specific concern, 80% of
radiation oncologists indicated that adjuvant radiotherapy would
be their preferred management for that patient. In the absence of
this concern, this increased to 96%. Many of the replies did
specifically state that sperm banking would be organized prior to
RT if necessary. There was a corresponding reduction in the
proportion of clinicians favouring surveillance as the preferred
option for the two scenarios, falling from 18 to 3%.Two radiation
oncologists replied that they would favour adjuvant chemo-
therapy in the situation where fertility was an issue for the patient
and in the absence of a fertility concern, this reduced to one.
Adjuvant radiotherapy
Seventy-five percent of Australasian radiation oncologists
elected a para-aortic field alone as their treatment volume.
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Thirty-four percent used a dog-leg and one described their
volume as an ‘amputated dog-leg’, which treated the para-aortic
and ipsilateral common iliac nodes. For the question regarding
dose-fractionation schedules, this latter volume was included
as a DL field.
Fifty-eight (79%) respondents prescribed a dose of 25 Gy in
either 15 (41%) or 20 (38%) fractions. Twelve percent used a
dose of 30 Gy in either 15 (7%) or 20 (5%) fractions (Table 2).
Forty-two of 48 radiation oncologists had changed their
treatment volume after the publication in 1999 of the MRC trial
comparing para-aortic with para-aortic plus ipsilateral pelvic
fields. Six had already been using the smaller volume and were
regarded as not being influenced by this trial.
Those clinicians treating their patients with PA RT were
asked to state the frequency of CT scanning to monitor the
pelvis. As per Table 3, most (40%) performed annual CT scans,
23% performed them every 6 months and 15 (31%) did none.
North American results
Seventy-three of 79 Canadians and 24 of 36 US radiation
oncologists returned the questionnaire.
Almost all radiation oncologists replied that they would order
CXR (99%) and CT scan of the abdomen and pelvis (100%) 
as a baseline evaluation. Only one obtained a thoracic CT scan
instead of CXR. Forty percent of North American radiation
oncologists ordered both chest CT and CXR. Lymphangiogram
was requested in 18%. Both lymphangiogam and thoracic CT
scan were more likely to be performed in the USA than Canada
(25% vs. 16%) and (45% vs. 38%), respectively.
Seventy-nine and 75% of Canadian and US respondents,
respectively, stated that they would routinely recommend
surveillance as a management option. When the option of
surveillance was raised, the median estimated proportion of
patients choosing it was 20% in Canada (range 0–100) and
7.5% in the US (range 0–50).
In Canada, the DL was more prevalent than the PA field 
(55 vs 42%), whereas in the USA, 54% used the PA field. Two
North American radiation oncologists routinely used a ‘modified
dog-leg’ that targeted the para-aortic and ipsilateral commmon
iliac regions.
The most frequently used dose-fractionation schedule in
North America was 25 Gy in 20 fractions (68%). In Canada, 
73 and 21% prescribed 25 Gy in either 20 or 15 fractions,
respectively. In the USA, 25 Gy in 20 fractions was most
commonly used (54%) with 21% prescribing 25–25.5 Gy in 17
fractions.
Twenty-six percent of Canadians utilizing PA RT reported
that they reduced their treatment volume from a dog-leg to para-
aortic as a result of the MRC study whereas 38% did so in the
USA.
Of those radiation oncologists using the PA field, 41 and
50% would perform a CT scan annually and every 6 months,
respectively, for 3 years in order to monitor the pelvis. Only 9%
did no follow-up CT scan.
DISCUSSION
There are several management approaches to Stage I test-
icular seminoma. This diversity partly reflects a paradigm shift
from that of maximizing cure to one of minimizing treatment-
related morbidity. Patient, treatment and tumour factors all play
a role in the management decision, as do patterns of referral
and the clinician’s preferences and recommendations. This
survey attempts to elicit management preferences among
radiation oncologists belonging to the RANZCR.
As parts of the questionnaire are identical to a survey
conducted in Canada and the USA during a similar period,
certain practices can be compared and contrasted. However, 
it must be noted that the groups targeted in these three 
areas differed markedly.The Canadian Association of Radiation
Oncologists has information on subsite specialization; therefore,
Table 1. In your practice, do you offer the patient the option of
surveillance, with salvage radiotherapy or chemotherapy reserved for
relapse?
Yes No No response
Number 40 33 1
Percentage 54 45
If yes, what proportion of your patients opt for the surveillance? 
14 = 0%, 4 = no response, 7 = 10%, 5 = 5%, 3 < 10%, 3 < 5%, 1 = 20%,
1 = 30%, 2 = 1%. Median 5%, range 0–30%.
Table 2. Post-operative adjuvant radiotherapy for Stage I seminoma
of testis?
Para-aortic Dog-leg Other Total
In this setting, what is your treatment volume?
n 48 25 1
% 65 34 1
In this setting, what dose fraction schedule do you use?
30Gy/20 fractions 2 2 4 (5%)
30Gy/15 fractions 3 2 5 (7%)
25Gy/20 fractions 18 10 28 (38%)
25Gy/15 fractions 22 8 30 (41%)
Other 3 4 7 (9%)
Table 3. If your treatment volume is the para-aortic region only, how




Every 6 months 11 23
Never 15 31
Other or no response 3 6
all radiation oncologists treating genitourinary tumours could 
be identified, and by contacting individual provincial regional
cancer centres, included in the survey. The survey was very
selectively targeted in the USA where it was distributed only to
the RTOG genitourinary committee members. By contrast, the
survey distributed by the RANZCR might be over-inclusive as it
targeted all practicing radiation oncologists affiliated with the
College. Hence, the Australasian survey should be regarded 
as a study of management preferences rather than a definitive
assessment of patterns of practice. At the opposite end of 
the spectrum, the US results reflect academic rather than
community practice in that country. Finally, for a more com-
prehensive view, it might be important to include urologists and
medical oncologists in future studies as they are involved in the
patterns of referral and care of these patients.
Radiological investigations
With the exception of one radiation oncologist who did not
answer any parts of the baseline investigation question, every-
one performed a CT scan of the abdomen and pelvis. However,
imaging of the thorax varied, with the majority (28) performing 
a CT scan, 24 ordering both CT and CXR, and 21 performing
CXR alone.Only one radiation oncologist in Australasia routinely
requested lymphangiography, reflecting both the invasive nature
of the procedure and the fact that few radiologists continue to
perform it given the availability of CT scanning. The ease of
access to CT might also explain the use of CT for evaluating the
thorax either instead of (38%) or in addition to (33%) CXR.
In North America, 40% of respondents ordered CT thorax in
addition to CXR. A baseline CXR was performed by all except
one clinician.The additional yield of thoracic CT in the presence
of a normal CXR is unknown. The use of lymphangiography
continues to be much more common in North America than
Australasia.
Management options
Many respondents (46% in the RANZCR) would not routinely
offer the option of surveillance despite increasing evidence 
that surveillance with reservation of RT and/or chemotherapy
for salvage appears not to compromise cure. There might be
several reasons for this reluctance. Surveillance requires com-
mitment by both the patient and their oncologist to intensive
monitoring. It also requires prolonged follow up as late relapse
(up to 9 years) is documented. Delay in the diagnosis of
recurrence in the poorly compliant or highly mobile patient
might compromise cure. Finally, surveillance carries both a
psychological or emotional as well as an economic cost.
The latter has been evaluated in two studies.12,13 In both, sur-
veillance was more expensive than adjuvant dog-leg RT.
Neither study incorporated the dollar cost of second malig-
nancies into their calculations as this data is as yet unavailable
for the surveillance series.
There was no significant difference in the proportion of
radiation oncologists offering the option of surveillance between
Canada and the USA. Both were more likely to offer surveillance
than members of the RANZCR. However, when asked to
estimate the proportion of patients choosing surveillance in 
their practice, there was a marked difference between the two
countries. In Canada, radiation oncologists estimated that a
median of 20% would opt for surveillance, whereas this estimate
was only 7.5% in the USA, perhaps reflecting the fact that the
Princess Margaret Hospital in Toronto, Canada, routinely offers
the option of surveillance, and has a large experience with this
approach. Locally, only ≤5% of patients were estimated to opt for
surveillance, and just over half (54%) of the clinicians stated that
they routinely offered this option.
When a patient had specific fertility concerns, 80% of
radiation oncologists indicated that adjuvant RT would be their
favoured management.This increased to 96% in the absence of
fertility preservation concerns. Thus, local radiation oncologists
tended to favour adjuvant RT. Several respondents specifically
stated that RT was their preferred alternative with the provision
that sperm banking was performed prior to treatment. The
survey did not examine the prevalence of cryopreservation 
prior to adjuvant treatment for this patient population. Some-
what surprisingly, two radiation oncologists favoured adjuvant
chemotherapy in the situation where fertility was an issue for
the patient. More data is needed in larger numbers of patients
in order to fully evaluate the acute and late toxicities of chemo-
therapy. Controversy also exists as to the dose and type of
agent, carboplatin has been shown to be inferior to cisplatin in
the treatment of non-seminomatous germ-cell tumours.14,15
Finally, although the Austrian trial of two cycles of adjuvant
carboplatin has no relapses amongst survivors, six patients
died of other causes, a surprisingly high rate for a relatively
young patient cohort.
Postoperative adjuvant RT
In Australasia, the MRC trial appears to have had a significant
impact upon the treatment volume for postoperative RT. Almost
two-thirds (65%) of responders indicated that the PA field was
their preferred volume, and of these, 88% stated that their
practice had changed after publication of this trial. Twenty-six
and 38% of Canadian and US clinicians changed their practice
as a consequence of the MRC trial. With respect to treatment
volumes, in Canada, a slight majority utilize the DL (58%), while
in the USA, 54% favour the PA field.
Although the MRC trial comparing PA with DL radiotherapy
was a large and well-conducted study, several issues remain
unresolved. Specifically, given the risk of pelvic relapse after 
PA treatment, the issue of monitoring the pelvis has not been
addressed. If follow-up pelvic CT is necessary and the MRC trial
suggests it is, how often should it be done? In the MRC trial, 
CT scans of the abdomen and pelvis were done annually for 
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3 years after RT in both arms. In the discussion section of the
MRC paper, it was suggested that CT scanning every 6 months
might be preferred for earlier detection of relapse as there were
four pelvic relapses in the PA group. However, only two were
isolated pelvic relapses, so the yield from scanning is very 
low. Philosophically, PA RT involves treating the most likely
anatomical area of relapse with observation of the pelvis.
Furthermore, the exact location of the four pelvic relapses 
(of which two were isolated) in the PA arm of the MRC trial were
not given. If, for example, all the pelvic recurrences occurred in
the common iliac lymph nodes, this raises the possibility that
the optimal treatment field might in fact extend from T11 to the
lower sacroiliac joints. Such a field would be associated with
less acute toxicity than a DL, but might be associated with an
even lower risk of pelvic relapse than PA alone, obviating the
need for pelvic surveillance.16
The majority of Australasian radiation oncologists (79%)
used a total dose of 25 Gy, delivered in either 15 (41%) or 20
(38%) fractions. For those treating to a total dose of 25 Gy, 
a slightly larger proportion of clinicians used 20 fractions if
treating a DL versus PA volume (56% vs 45%). Only 12% of
radiation oncologists used a total dose of 30 Gy.Thus, although
the MRC trial has greatly affected local practice with respect to
treatment volumes, a minority use the MRC dose/fractionation
schedule (30 Gy in 15 fractions).
In North America, this effect is also evident with only 2% 
of North American radiation oncologists used 30 Gy in 15
fractions. The Canadians in particular have very uniform dose
prescribing practices with 73% using 25 Gy in 20 fractions.
The frequency of pelvic CT scans after adjuvant PA RT varies
between countries and individuals. In Australasia, 40% of
radiation oncologists performed annual abdominal and pelvic CT
scans, 23% organized scans for their patients every 6 months
while 31% did not subsequently image the pelvis. By contrast,
in North America, only 9% did not monitor the pelvis with the
majority of clinicians divided between annual or twice-yearly 
CT scanning (41 and 50%, respectively). Although the MRC
trial recommended, but did not substantiate CT scans every 
6 months, this is an area that requires further investigation.
CONCLUSION
There has been a trend towards using a smaller RT volume,
strongly influenced by the published MRC trial. However, there
is little consensus with respect to pelvic follow up after PA
irradiation. Although 54% of radiation oncologists discuss the
option of surveillance, few patients select this option.
Compared to North America, we are more likely to use 
PA fields and less likely to discuss surveillance as an option.
A minority of our patients will opt for surveillance where this
management alternative is discussed with the patient. Finally,
although North American radiation oncologists are more likely
than Australasians to perform CT scans of the pelvis after 
PA treatment, there is no consensus regarding the frequency of
these scans in any of these countries.
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